Cargando…

Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide

BACKGROUND: Phosphate binders are widely used to achieve serum phosphorus control in patients with end-stage renal disease. However, the large pill burden associated with these medications may decrease adherence to therapy. In clinical trials, sucroferric oxyhydroxide (SO) demonstrated equivalent co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gray, Kathryn, Ficociello, Linda H, Hunt, Abigail E, Mullon, Claudy, Brunelli, Steven M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348967/ https://www.ncbi.nlm.nih.gov/pubmed/30774412 http://dx.doi.org/10.2147/IJNRD.S182747

Ejemplares similares

One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis
por: Kendrick, Jessica, et al.
Publicado: (2019)

Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort
por: Kendrick, Jessica B, et al.
Publicado: (2022)

Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study
por: Coyne, Daniel W., et al.
Publicado: (2020)

Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2019)

A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care
por: Rhee, Connie M., et al.
Publicado: (2022)

Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
por: Coyne, Daniel W., et al.
Publicado: (2017)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients
por: Abdelbary, Mohamed M. H., et al.
Publicado: (2022)

Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide
por: Stavroulopoulos, Aristeidis, et al.
Publicado: (2018)

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study
por: Yaguchi, Atsushi, et al.
Publicado: (2019)

The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial
por: Thiem, Ursula, et al.
Publicado: (2020)

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients
por: Shima, Hisato, et al.
Publicado: (2018)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model
por: Nemoto, Yoshikazu, et al.
Publicado: (2019)

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study
por: Merino-Ribas, Ana, et al.
Publicado: (2021)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease
por: Greenbaum, Larry A., et al.
Publicado: (2020)

The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
por: Ramos, Rosa, et al.
Publicado: (2020)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure
por: Neven, Ellen, et al.
Publicado: (2020)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2021)

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
por: Cernaro, Valeria, et al.
Publicado: (2016)

Effect of Citrate-Acidified Dialysate on Intact Parathyroid Hormone in Prevalent Hemodialysis Patients: A Matched Retrospective Cohort Study
por: Ficociello, Linda H, et al.
Publicado: (2021)

Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure
por: Phan, Olivier, et al.
Publicado: (2015)

Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects
por: Chong, Edward, et al.
Publicado: (2014)

Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study
por: Ferreira, Aníbal, et al.
Publicado: (2019)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis
por: Perez, Luis, et al.
Publicado: (2022)

Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis
por: Wang, Steven, et al.
Publicado: (2014)

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation
por: Floege, Jürgen, et al.
Publicado: (2020)

Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis
por: Martins, Maria Tereza Silveira, et al.
Publicado: (2013)

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
por: Gutzwiller, Florian S., et al.
Publicado: (2015)

Effectiveness and cost-efficiency of phosphate binders in hemodialysis
por: Fröschl, Barbara, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8jnkkig3vmafvclumdbucu7s14